Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Loading...
Behavioral FinanceMost Recent Stories

Valeant and the Gambler’s Dilemma

If you’ve been paying attention to the financial media in the last few weeks you’ve probably seen the drama surrounding a company named Valeant.  In case you’ve been buried in your bunker waiting for China to blow up the global economy, here’s the short version – Valeant is a pharmaceutical company that has basically acquired its way to massive growth by gobbling up smaller firms, raising prices and restructuring.  They’ve become a pharmacy, but with huge pricing power thanks to their increased monopoly power.  Anyhow, a number of research outfits have come out in recent months discussing various accounting and corporate discrepancies.  Some have even called Valeant the next Enron.

Anyhow, the stock has been sliced by 70% in the last few months.  And this situation raises all sorts of thoughts for investors:

  • Should most investors be involved in asset allocation that exposes them to so much single entity risk?
  • If your answer is no, then indexing is your obvious route.
  • If your answer is yes, then you better have a damn good way of analyzing the risks in your portfolio so as to reduce single entity risk.

And this is where a lot of stock pickers get into trouble.  While indexing reflects the positive sum nature of the economy over long periods of time stock picking can often times look more like negative sum gambling (especially when done in a highly active, tax and fee inefficient manner).  In the case of something like Valeant it can actually look like something worse than gambling.  After all, when you gamble, you are playing a negative sum game where the probable outcomes can be calculated.  But in the case of Valeant we have no idea what the probable outcomes are. After all, if this is a fraud then the stock is going to $0.  Does anyone except insiders really know at this point?  I doubt it.

Gambling isn’t what people should do with their savings.  And that’s part of what makes stock picking so risky at times.  You’re dealing with complex components of a complex system where you can’t possibly know the possible outcomes at times.  So ask yourself – are you a saver or a gambler?  I don’t know what your answer is, but in either case you can probably calculate the simple odds about what my concluding thoughts here would be.